Introduction
muscle weakness, mood disorders, fatigue, Myasthenia, autoimmune disease
TREATMENT SIDE EFFECTS, MUSCLE WEAKNESS, DISEASE, MYASTHENIA, SECONDARY, AUTOIMMUNE DISEASE
Myasthenia gravis (MG) is a rare, chronic autoimmune disease characterized by debilitating and potentially life-threatening muscle weakness and fatigue [Approximately 50% of patients with MG have mood disorders [Treatments for MG include acetylcholinesterase (AChE) inhibitors to control symptoms and immunosuppressive medications and thymectomy in individuals with acetylcholine receptor antibody–positive (AChR-Ab+) MG. Immunosuppressants used to treat MG include corticosteroids, nonsteroidal immunosuppressant therapies (NSISTs), and monoclonal antibodies such as rituximab, eculizumab, and ravulizumab [Unsurprisingly, patients with MG whose disease symptoms are not controlled adequately with therapy or who have a high level of treatment side effects or burden report the lowest HRQoL [The phase 3 ADAPT study (NCT03669588) [The purpose of this secondary analysis is to report the HRQoL outcomes from participants with AChR-Ab+ gMG in the ADAPT study, across 2 cycles of treatment and follow-up. HRQoL measures used included the Myasthenia Gravis-Quality of Life 15-item revised (MG-QoL15r), which is an MG-specific measure, and the EuroQoL 5-Dimensions 5-Levels (EQ-5D-5L), including visual analog scale (VAS), which is a generic measure used across disease states.